Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Andrew, Feigin"'
Autor:
Tom Ettinger, Marygrace Berberian, Ikuko Acosta, Alberto Cucca, Andrew Feigin, Danilo Genovese, Travis Pollen, Julianne Rieders, Rohita Kilachand, Clara Gomez, Girija Kaimal, Milton Biagioni, Alessandro Di Rocco, Felice M. Ghilardi, John-Ross Rizzo
Publikováno v:
Frontiers in Human Neuroscience, Vol 17 (2023)
IntroductionParkinson’s disease (PD) is the second most prevalent neurodegenerative disease. Complementary and alternative therapies are increasingly utilized to address its complex multisystem symptomatology. Art therapy involves motoric action an
Externí odkaz:
https://doaj.org/article/aaa65a3f580b4814ac6dfdf664487209
Autor:
Gregory Vurture, Benoit Peyronnet, Jose-Alberto Palma, Rachael D. Sussman, Dominique R. Malacarne, Andrew Feigin, Ricardo Palmerola, Nirit Rosenblum, Steven Frucht, Horacio Kaufmann, Victor W. Nitti, Benjamin M. Brucker
Publikováno v:
International Neurourology Journal, Vol 23, Iss 3, Pp 211-218 (2019)
Purpose To assess the urodynamic findings in patients with Parkinson disease (PD) with overactive bladder symptoms. Methods We performed a retrospective chart review of all PD patients who were seen in an outpatient clinic for lower urinary tract sym
Externí odkaz:
https://doaj.org/article/5b80d81f344b44f2a6445ecc5ae6f5a5
Autor:
Andrew Feigin, Milton C. Biagioni, Matilde Inglese, Angelo Quartarone, Marygrace Berberian, Mahya Beheshti, Ikuko Acosta, Amgad Droby, Hilary Bertisch, M. Felice Ghilardi, Kush Sharma, Alessandro Di Rocco, Yoon J. Jung, John Ross Rizzo, Daniella F. Mania, Tom Ettinger, Todd E. Hudson, Alberto Cucca
Publikováno v:
Parkinsonism & Related Disorders. 84:148-154
Objective To explore the potential rehabilitative effect of art therapy and its underlying mechanisms in Parkinson's disease (PD). Methods Observational study of eighteen patients with PD, followed in a prospective, open-label, exploratory trial. Bef
Autor:
Angela C. Roberts, Miriam R. Rafferty, Samuel S. Wu, Guanhuong Miao, Fernando Cubillos, Tanya Simuni, Connie Marras, Tom Davis, Nabila Dahodwala, Marilyn Neault, Adolfo Ramirez-Zamora, Miriam Rafferty, Irene Malaty, Sotirios Parashos, Jeff Kraakevik, Joseph Jankovic, David Simon, Rajesh Pahwa, Kelly Mills, Christopher Way, John Morgan, Fernando Pagan, Robert Hauser, Thomas Davis, Naomi Salins, Tanya Gurevich, Bastiaan Bloem, Carlos Singer, Anne Louise Lafontaine, Andrew Feigin, Janis Miyasaki, Irene Litvan
Publikováno v:
Parkinsonism & Related Disorders. 83:115-122
Introduction Rehabilitation therapies are critical for optimizing quality-of-life and daily functions for individuals living with Parkinson's disease (PD). Thus, understanding the patterns of and under what conditions physicians make rehabilitation r
Autor:
David Eidelberg, Matthew Hellman, Shichun Peng, Yilong Ma, Koji Fujita, Vijay Dhawan, Chris C. Tang, Andrew Feigin
Publikováno v:
Journal of Neurology. 268:2246-2255
Recent studies on a rodent model of Parkinson’s disease (PD) have raised the possibility of increased blood–brain barrier (BBB) permeability, demonstrated by histology, autoradiography, and positron emission tomography (PET). However, in human PD
Autor:
Florian Holtbernd, Chris C Tang, Andrew Feigin, Vijay Dhawan, Maria Felice Ghilardi, Jane S Paulsen, Mark Guttman, David Eidelberg
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0154742 (2016)
Neurocognitive decline, including deficits in motor learning, occurs in the presymptomatic phase of Huntington's disease (HD) and precedes the onset of motor symptoms. Findings from recent neuroimaging studies have linked these deficits to alteration
Externí odkaz:
https://doaj.org/article/8d319b3009774f7fbdf3df5aec5a8dc2
Autor:
Andrew, Feigin, Elizabeth E, Evans, Terrence L, Fisher, John E, Leonard, Ernest S, Smith, Alisha, Reader, Vikas, Mishra, Richard, Manber, Kimberly A, Walters, Lisa, Kowarski, David, Oakes, Eric, Siemers, Karl D, Kieburtz, Maurice, Zauderer, Karen, Anderson
Publikováno v:
Nature medicine. 28(10)
SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D (SEMA4D)-blocking antibody, for treatment of Huntington's disease (HD). The trial enrolled a tota
Autor:
Michael R. Hayden, Yael C Cohen, Ralf Reilmann, C. Warren Olanow, Karl Kieburtz, Sandra K. Kostyk, Michal Geva, Andrew Feigin, Munish Mehra, Andrew McGarry, Anne Elizabeth Rosser, Noga Gershoni-Emek
Publikováno v:
F: Clinical studies: case reports, observational studies and trials.
Autor:
Robert Wiggins, Andrew Feigin
Publikováno v:
Expert opinion on emerging drugs. 26(3)
Huntington's disease is a neurodegenerative disease that is characterized by motor dysfunction, behavioral/psychiatric symptoms, and cognitive impairment. Because of the lack of availability of curative or disease modifying treatments, much of clinic
Autor:
Rachael D. Sussman, Andrew Feigin, R. Palmerola, B. Peyronnet, Jose-Alberto Palma, Victor W. Nitti, Benjamin M. Brucker, Nirit Rosenblum, Gregory Vurture, Steven J. Frucht, Dominique R. Malacarne, Horacio Kaufmann
Publikováno v:
International Neurourology Journal
International Neurourology Journal, Vol 23, Iss 3, Pp 211-218 (2019)
International Neurourology Journal, Vol 23, Iss 3, Pp 211-218 (2019)
Purpose To assess the urodynamic findings in patients with Parkinson disease (PD) with overactive bladder symptoms. Methods We performed a retrospective chart review of all PD patients who were seen in an outpatient clinic for lower urinary tract sym